RNA-seq of human liver cancer cell line HepG2 treated with doxorubicin alone or in combination with valproic acid or suberoylanilide hydroxamic acid against untreated controls
RNA sequencing was performed to characterize transcriptomic changes in the human hepatocellular carcinoma cell line HepG2 following treatment with doxorubicin (DOX), either alone or in combination with the histone deacetylase inhibitors valproic acid (VPA) or suberoylanilide hydroxamic acid (SAHA), relative to untreated controls.  HepG2 cells were exposed to the indicated treatments for 48 hours. Total RNA was extracted, and poly(A)-enriched stranded libraries were prepared. Paired-end sequencing was conducted on an Illumina platform. Reads were aligned to the human reference genome (GRCh38), followed by gene-level quantification and differential gene expression analysis.  This dataset enables analysis of transcriptional programs associated with HDAC inhibition and modulation of DOX response, including pathways related to DNA repair, stress response, and p53 signaling.